Intranasal PUVA phototherapy in nasal polyposis--a pilot study.

Andrea Koreck, Zsolt Bella, Edit Kadocsa, Adam Perenyi, Laszlo Tiszlavicz, Istvan Nemeth, Maria Kiss, Tudor Rares Olariu, Jozsef Jori, Lajos Kemeny

Research output: Contribution to journalArticle

4 Citations (Scopus)


Nasal polyposis (NP) affects 4% of the general population, representing a major health problem. In spite of complex (surgical and medical) treatment, the relapse rate is high and it has a negative impact on the quality of life. Recently we found that intranasal photochemotherapy with ultraviolet A light (PUVA) is effective in allergic rhinitis. In the present study PUVA was administered for 6 weeks in 7 patients with NP. Nasal lavages were performed in all patients before and at the end of the treatment; from four patients a biopsy specimen was also collected. Eosinophils significantly decreased in patients with NP and slightly in a patient who had associated aspirin sensitivity. IL-5 and eosinophil cationic protein (ECP) levels showed a decreasing trend in patients with NP and an increasing trend in patients with associated aspirin sensitivity. Our results suggest that intranasal PUVA might represent a future therapeutic method in a subset of patients with NP.

Original languageEnglish
Pages (from-to)20-23
Number of pages4
JournalRoumanian archives of microbiology and immunology
Issue number1
Publication statusPublished - Jan 1 2010


ASJC Scopus subject areas

  • Medicine(all)

Cite this